RDHL Stock Price | Redhill Biopharma Ltd P/E, Revenue, EPS, & Forecasts

Redhill Biopharma Ltd • RDHL

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Redhill Biopharma Ltd

Ticker

RDHL

Trading on

NASDAQ

ISIN

US7574681034

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

CEO

Dror Ben-Asher

Headquarters

21 Ha’arba’a Street, Tel Aviv, undefined, Israel, 6473921

Employees

Website

redhillbio.com

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Metrics

BasicAdvanced

Market cap

$4.3M

P/E ratio

EPS

$0.00

Dividend Yield

0.00%

Beta

4.22

Forward P/E ratio

1,428.57

EBIDTA

$-12.2M

Ex dividend date

Price & volume

Market cap

$4.3M

Average daily volume

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

1,428.57

PEG ratio

Trailing P/E

Price to sales

0.54

Price to book

203.21

Earnings

EPS

$0.00

EPS estimate (current quarter)

$0.00

EPS estimate (next quarter)

$0.00

EBITDA

$-12.2M

Revenues (TTM)

$8M

Revenues per share (TTM)

$6.53

Technicals

Beta

4.22

52-week High

$20.28

52-week Low

$1.71

50-day moving average

$2.01

200-day moving average

$5.37

Short ratio

0.45

Short %

4.41%

Management effectiveness

ROE (TTM)

-1,708.61%

ROA (TTM)

-37.28%

Profit margin

-102.80%

Gross profit margin

$4.9M

Operating margin

-69.57%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

382.00%

Share stats

Outstanding Shares

2.3M

Float

11.5B

Insiders %

Institutions %

5.67%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

$19,000.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.20

-$0.03

-566.67%

Q3 • 22Missed

-$0.20

Q4 • 22Beat

-$1.60

Q1 • 23Beat

$0.26

Q2 • 23Beat

Q3 • 23Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$3.6M

$50.2M

1,395.97%

Q1 • 23

$1.8M

$0.8M

42.37%

Q2 • 23

-50.10%

-98.49%

-96.96%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$18M

$22.7M

125.95%

Q4 • 24

$18M

$22.7M

125.95%

Q1 • 25

0.00%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-10.6M

$-0M

$0M

$-10.6M

Q2 • 23

Q4 • 23

NaN%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Redhill Biopharma Ltd share?

Redhill Biopharma Ltd shares are currently traded for undefined per share.

How many shares does Redhill Biopharma Ltd have?

Redhill Biopharma Ltd currently has 2.3M shares.

Does Redhill Biopharma Ltd pay dividends?

No, Redhill Biopharma Ltd doesn't pay dividends.

What is Redhill Biopharma Ltd 52 week high?

Redhill Biopharma Ltd 52 week high is $20.28.

What is Redhill Biopharma Ltd 52 week low?

Redhill Biopharma Ltd 52 week low is $1.71.

What is the 200-day moving average of Redhill Biopharma Ltd?

Redhill Biopharma Ltd 200-day moving average is $5.37.

Who is Redhill Biopharma Ltd CEO?

The CEO of Redhill Biopharma Ltd is Dror Ben-Asher.

How many employees Redhill Biopharma Ltd has?

Redhill Biopharma Ltd has 35 employees.

What is the market cap of Redhill Biopharma Ltd?

The market cap of Redhill Biopharma Ltd is $4.3M.

What is the P/E of Redhill Biopharma Ltd?

The current P/E of Redhill Biopharma Ltd is 0.

What is the EPS of Redhill Biopharma Ltd?

The EPS of Redhill Biopharma Ltd is $0.00.

What is the PEG Ratio of Redhill Biopharma Ltd?

The PEG Ratio of Redhill Biopharma Ltd is 0.

What do analysts say about Redhill Biopharma Ltd?

According to the analysts Redhill Biopharma Ltd is considered a buy.